Cardiovascular Systems Stock Forecast, Price & News

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CSII shares have decreased by 4.0% and is now trading at $34.85.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cardiovascular Systems or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Cardiovascular Systems a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cardiovascular Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Cardiovascular Systems.

Cardiovascular Systems, Inc. (NASDAQ:CSII) posted its earnings results on Wednesday, November, 4th. The medical device company reported ($0.05) EPS for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.18. The medical device company earned $60.54 million during the quarter, compared to analysts' expectations of $56.27 million. Cardiovascular Systems had a negative net margin of 10.12% and a negative return on equity of 11.43%.
View Cardiovascular Systems' earnings history.

Cardiovascular Systems issued an update on its second quarter 2021 After-Hours earnings guidance on Wednesday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63-67 million, compared to the consensus revenue estimate of $66.01 million.

7 brokerages have issued 12-month price objectives for Cardiovascular Systems' shares. Their forecasts range from $40.00 to $48.00. On average, they anticipate Cardiovascular Systems' stock price to reach $45.57 in the next year. This suggests a possible upside of 30.8% from the stock's current price.
View analysts' price targets for Cardiovascular Systems.

Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD) and STERIS (STE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), Xcel Energy (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and The Procter & Gamble (PG).

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Cardiovascular Systems' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.99%), Champlain Investment Partners LLC (7.38%), State Street Corp (3.39%), New York State Common Retirement Fund (1.96%), ArrowMark Colorado Holdings LLC (1.38%) and Peregrine Capital Management LLC (1.15%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb and Sandra Sedo.
View institutional ownership trends for Cardiovascular Systems.

CSII stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Peregrine Capital Management LLC, Sei Investments Co., First Quadrant L P CA, Victory Capital Management Inc., JPMorgan Chase & Co., AQR Capital Management LLC, and Gamco Investors INC. ET AL. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, and Sandra Sedo.
View insider buying and selling activity for Cardiovascular Systems.

CSII stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Grandeur Peak Global Advisors LLC, Point72 Asset Management L.P., State Street Corp, Segall Bryant & Hamill LLC, Perkins Capital Management Inc., Millrace Asset Group Inc., and Aigen Investment Management LP. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Martha Goldberg Aronson, and Rhonda J Robb.
View insider buying and selling activity for Cardiovascular Systems.

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CSII stock can currently be purchased for approximately $34.85.

Cardiovascular Systems has a market capitalization of $1.40 billion and generates $236.54 million in revenue each year. The medical device company earns $-27,240,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cardiovascular Systems employs 779 workers across the globe.

The official website for Cardiovascular Systems is www.csi360.com.

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]